Treace Medical Concepts, Inc. (TMCI) stock
Close on Nov 17, 2026Market cap $288.75MP/E –Yield –
Earnings
Treace Medical Concepts's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Treace Medical Concepts's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 26, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 6, 2026before the open | $48.30M | -3.8% | -$0.19 | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 7, 2026before the open | $45.40M | -4.2% | -$0.24 | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 8, 2026before the open | $47.20M | -10.3% | -$0.28 | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 27, 2026before the open | $62.50M | -9.0% | -$0.15 | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | $50.20M | +11.3% | -$0.26 | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | $47.40M | +6.5% | -$0.28 | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | $52.60M | +2.9% | -$0.25 | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025after the close | $68.70M | +10.5% | -$0.01 | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 5, 2024after the close | $45.10M | +10.5% | -$0.25 | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024after the close | $44.50M | +6.0% | -$0.34 | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024after the close | $51.10M | +21.1% | -$0.30 | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024after the close | $62.20M | +24.9% | -$0.10 | -$0.10 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023after the close | $40.80M | +23.3% | -$0.28 | -$0.28 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023after the close | $42.00M | +40.0% | -$0.20 | -$0.20 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 8, 2023after the close | $42.20M | +45.5% | -$0.23 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 7, 2023after the close | $49.80M | +49.1% | -$0.08 | -$0.08 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022after the close | $33.10M | +53.2% | -$0.22 | -$0.22 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022after the close | $30.00M | – | -$0.31 | -$0.23 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | $29.00M | – | -$0.16 | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 3, 2022after the close | $33.40M | – | -$0.12 | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021after the close | $21.60M | – | -$0.12 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 25, 2021after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Treace Medical Concepts's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| decline | FY2026 | -4% – 0% | – | New | Aug 7, 2026 |
| revenueGAAP | FY2026 | $206.00M – $210.00M | $202.00M – $212.00M | Narrowed | Nov 6, 2026 |
| revenue | FY2026 | $200.00M – $212.00M | – | New | Feb 27, 2026 |
| revenue guidance | FY2026 | $204.00M – $212.00M | – | New | Aug 7, 2026 |
| loss in Adjusted EBITDAnon-GAAP | FY2026 | $1.00M – $2.00M | $4.00M – $6.00M | Lowered | Nov 6, 2026 |
| loss in Adjusted EBITDAnon-GAAP | FY2026 | -$5.00M – -$3.00M | – | New | Aug 7, 2026 |
| reduction in cash usage | FY2026 | +50% | +50% | Reaffirmed | Nov 6, 2026 |
| reduction in cash usage | FY2026 | 50% | – | New | Aug 7, 2026 |
| reduction in cash usage | FY2026 | 50% | – | New | May 8, 2026 |
Guidance vs results
The last range Treace Medical Concepts gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $211.00M – $213.00M | $212.70MΣ4Q | Within range |
| FY2025 | Revenue growth | +1% – +2% | +1.58%Σ4Q | Within range |
Guidance history
Every forecast Treace Medical Concepts put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 6, 2026 | loss in Adjusted EBITDA | FY2026 | $1.00M – $2.00M | Lowered |
| Nov 6, 2026 | reduction in cash usage | FY2026 | +50% | Reaffirmed |
| Nov 6, 2026 | revenue | FY2026 | $206.00M – $210.00M | Narrowed |
| Aug 7, 2026 | loss in Adjusted EBITDA | FY2026 | -$5.00M – -$3.00M | New |
| Aug 7, 2026 | reduction in cash usage | FY2026 | 50% | New |
| Aug 7, 2026 | decline | FY2026 | -4% – 0% | New |
| Aug 7, 2026 | revenue guidance | FY2026 | $204.00M – $212.00M | New |
| May 8, 2026 | loss in Adjusted EBITDA | FY2026 | $4.00M – $6.00M | Reaffirmed |
| May 8, 2026 | reduction in cash usage | FY2026 | 50% | New |
| May 8, 2026 | revenue guidance | FY2026 | $202.00M – $212.00M | New |
| Feb 27, 2026 | Adjusted EBITDA | FY2026 | $4.00M – $6.00M | New |
| Feb 27, 2026 | reduction in cash usage | FY2026 | +50% | New |
| Feb 27, 2026 | revenue | FY2026 | $200.00M – $212.00M | New |
| Nov 6, 2025 | Adjusted EBITDA improvement | FY2025 | +32% – +41% | New |
| Nov 6, 2025 | loss in Adjusted EBITDA | FY2025 | $6.50M – $7.50M | New |
| Nov 6, 2025 | reduction in cash used | FY2025 | 43% – 47% | New |
| Nov 6, 2025 | revenue growth | FY2025 | +1% – +2% | New |
| Nov 6, 2025 | revenue | FY2025 | $211.00M – $213.00M | New |
| Aug 7, 2025 | growth | FY2025 | +7% – +10% | Reaffirmed |
| Aug 7, 2025 | revenue guidance | FY2025 | $224.00M – $230.00M | Reaffirmed |
| May 8, 2025 | growth | FY2025 | +7% – +10% | New |
| May 8, 2025 | revenue | FY2025 | $224.00M – $230.00M | Reaffirmed |
| Feb 27, 2025 | revenue | FY2025 | $224.00M – $230.00M | New |
| Nov 5, 2024 | Adjusted EBITDA loss decrease | FY2024 | 50% | New |
| Nov 5, 2024 | revenue growth | FY2024 | +9% – +13% | New |
| Nov 5, 2024 | revenue | FY2024 | $204.00M – $211.00M | Raised |
| Aug 6, 2024 | Adjusted EBITDA | FY2024 | +50% | Reaffirmed |
| Aug 6, 2024 | revenue | FY2024 | $201.00M – $211.00M | Reaffirmed |
| May 7, 2024 | Adjusted EBITDA | FY2024 | +50% | Reaffirmed |
| May 7, 2024 | revenue | FY2024 | $201.00M – $211.00M | Lowered |
| Feb 27, 2024 | Adjusted EBITDA | FY2024 | +50% | New |
| Feb 27, 2024 | revenue | FY2024 | $220.00M – $225.00M | New |
| Nov 9, 2023 | revenue | FY2023 | $182.00M – $186.00M | Lowered |
| Aug 8, 2023 | revenue | FY2023 | $191.00M – $197.00M | Raised |
| May 8, 2023 | revenue guidance | FY2023 | $190.00M – $196.00M | Raised |
| Mar 7, 2023 | revenue | FY2023 | $187.00M – $193.00M | New |
| Nov 8, 2022 | revenue | FY2022 | $135.00M – $138.00M | Raised |
| Aug 9, 2022 | revenue | FY2022 | $130.00M – $134.00M | Raised |
| May 5, 2022 | revenue | FY2022 | $128.00M – $133.00M | Raised |
| Mar 3, 2022 | revenue | FY2022 | $125.00M – $130.00M | New |
| Nov 4, 2021 | revenue | FY2021 | $90.00M – $95.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Treace Medical Concepts filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
See a number that looks wrong?